We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

PANalytical Launched New Compact Benchtop XRF System

Read time: Less than a minute

PANalytical has launched a new Epsilon 1 XRF (X-ray fluorescence) analyzer at last year’s meeting of the American Association of Pharmaceutical Sciences (AAPS), November 2-6, in San Diego, California.

Designed as the most powerful benchtop spectrometer in its class, the new Epsilon 1 provides a compact and cost-effective ‘out-of-the-box’ pre-calibrated solution for the analysis of residual catalysts in pharmaceutical materials.

Metal catalysts are used as part of the pharmaceutical development and manufacturing processes. Post-process efforts are made to remove the undesired catalyst from the material but there are often residues remaining.

These residues require comprehensive quantification to meet stringent industry permissible limits, such as those specified in pharmacopoeias including the United States pharmacopoeia and the European pharmacopoeia. The Epsilon 1 will set the new benchmark for analytical performance and ease of use in this class of industry-dedicated XRF instrumentation.

“The need for pharmaceutical catalyst analysis is an industry-wide concern,” commented Pieter de Groot, PANalytical Corporate Marketing Director. “The Epsilon 1 offers a pre-calibrated total solution package, including installation qualification and operation qualification procedures. Designed with simplicity in mind, for the first time PANalytical’s high standards of analysis are now available in this class of desktop instruments.”